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Abstract
Deficiency of lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS) leads to mucopolysaccharidosis IV A
(MPS IV A), for which there is no definitive treatment so far. Although a number of mutations of the GALNS gene of MPS
IV A patients have been described, pathogenesis of the disorder still remains elusive. In order to facilitate in vivo studies
using model animals for MPS IV A, we isolated and performed molecular characterization of the mouse homolog of human
GALNS. The 2.3-kb cDNA contains a 1560-bp open reading frame encoding 520 amino acid residues. The coding region has
84% similarity to the human GALNS cDNA at amino acid level. The mouse Galns gene was mapped by interspecific
backcross analysis to the distal region of chromosome 8 where it co-segregates with Aprt. Northern blot analysis showed a
wide expression of a single-copy gene, being higher especially in liver and kidney. The Galns gene was isolated from S129vJ
genomic library and its genomic organization was characterized. The mouse Galns gene was about 50-kb long and organized
into 14 exons and 13 introns. All intron^exon splice junctions conformed to the GT/AG consensus sequence except exon
8/intron 8 junction. Primer extension shows multiple transcription initiation sites between 344 and 375 although major
transcription initiation site was observed at 390 bp from the ATG codon. The 5P-flanking region lacks canonical TATA and
CAAT box sequences, but is G+C rich with 10 GC boxes (potential Sp1 binding sites), characteristic of a housekeeping gene
promoter. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mucopolysaccharidosis IV A (MPS IV A) is an
autosomal recessive disorder caused by the de¢ciency
of the lysosomal enzyme, N-acetylgalactosamine-6-
sulfate sulfatase (GALNS, EC 3.1.6.4). This enzyme
hydrolyzes the sulfate ester bonds of N-acetyl-galac-
tosamine-6-sulfate at the non-reducing end of chon-
droitin-6-sulfate and galactose-6-sulfate at the non-
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reducing end of keratan sulfate [1,2]. The defect of
GALNS causes lysosomal accumulation and urinary
secretion of predominantly keratan sulfate and chon-
droitin sulfate. Unlike other mucopolysaccharidoses,
classic MPS IV A patients keep normal intelligence.
However, the storage mainly a¡ects the bone system
leading to severe bone dysplasia, coxa valga and
odontoid hypoplasia [3]. This results in various com-
plicated symptoms, such as gait disturbance, kypho-
scoliosis, short stature, restriction of e⁄cient breath-
ing, feasibility of infection and instability of cervical
spine. Especially cervical instability and pulmonary
infection cause the death of the patient in the second
or third decade of life. In addition to the classic type,
MPS IV A patients present a wide variety of clinical
phenotypes including attenuated and mild types
characterized by mild bone involvement, mild viscer-
al organ involvement and normal quality of life [4,5].
Previously, human GALNS cDNA [6] and ge-
nomic gene organization [7] have been described.
The cDNA has 2339 nucleotides, 1566 of which
code for the 522 amino acids. One major mRNA
species of 2.3 kb is transcribed from the gene. The
promoter of the human GALNS gene lacks TATA
and CAAT boxes, but contains four Sp1 binding
sites. The human GALNS gene has been assigned
to chromosome 16q24 by in situ hybridization to
metaphase chromosomes [8^10]. Approximately 90
mutations of GALNS gene, which are responsible
for phenotypic diversity, have been characterized in
human patients [11^21]; but the mechanism how dif-
ferent mutations lead to phenotypic variations and
their pathogenesis is still unclear.
Up to now, several model animals have been re-
ported in MPS I [22^24], MPS II [25], MPS III A
[26], MPS III B [27], MPS III D [28], MPS VI [29,30]
and MPS VII [31^33], but none in MPS IV A yet.
The availability of an animal model will give us bet-
ter insight into the pathogenesis of the disorder
which may lead to the development of novel thera-
peutic strategies.
Here we report the isolation and expression of
mouse Galns cDNA and its chromosomal localiza-
tion together with the genomic organization and pro-
moter analysis of the mouse Galns gene. We will also
discuss similarities and di¡erences in the cDNA se-
quence and in the organization of the gene between
human and mouse.
2. Materials and methods
2.1. Cloning of mouse Galns cDNA
Clones (1U106) of a genomic library from mouse
¢broblasts in Vgt10 vector (kindly provided by Dr. E.
Namba; Department of Pediatric Neurology, School
of Medicine, Tottori University, Japan) were
screened using a fragment of 608 bp of human
GALNS cDNA as a probe [6]. This probe was ob-
tained by PCR ampli¢cation of human GALNS
cDNA as follows: 40 cycles (94‡C, 1 min; 45‡C,
2 min; 72‡C, 7 min) with primers OMF 7: TGAAG-
CACGGATTTGATGAGT (510^530, sense) and
OMF 25: GCCCGCAAGGGCCAGGCTGGT
(1117^1097, antisense) using LATaq polymerase (Ta-
kara Shuzo, Japan).
The human GALNS cDNA probe was [K-32P]-
dCTP (Amersham-Pharmacia Biotech) labeled and
hybridization was done according to the manufactur-
er’s instructions. Five positive clones were subjected
to several rounds of plaque puri¢cation. cDNA in-
serts of V2.3 kb were excised by digestion with
EcoRI and subcloned into pUC 18 vector. Sequenc-
ing was performed in both directions using a Perkin
Elmer-Applied Biosystems 377 Automated Se-
quencer.
2.2. Enzyme expression
We cloned the full-length mouse cDNA (V2.3 kb)
into the pCAGGS expression vector that was kindly
provided by Dr. J. Miyazaki (University of Tokyo,
Japan)[34]. Eight micrograms of this construct, des-
ignated as pMMYN, were transfected into human
GALNS de¢cient ¢broblasts by the liposome-medi-
ated transfection method (Gene Transfer, Wako, Ja-
pan), according to the manufacturer’s instructions.
After 96 h, cultured ¢broblasts were harvested for
enzyme activity measurement. The enzyme activity
was measured as previously described [35].
2.3. Chromosomal mapping of the mouse Galns gene
Interspeci¢c backcross progeny were generated by
mating (C57BL/6JUMus spretus) F1 females and
C57BL/6J males as described [36]. A total of 205
N2 mice were used to map the Galns locus. DNA
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isolation, restriction enzyme digestion, agarose gel
electrophoresis, Southern blot transfer and hybrid-
ization were performed essentially as described [37].
All blots were prepared with Hybond-N+ nylon
membrane (Amersham). The probe, an V2.3-kb
EcoRI fragment of mouse cDNA, was labeled with
[K-32P]dCTP using a nick translation labeling kit
(Boehringer Manheim); washing was done to a ¢nal
stringency of 1.0USSPE, 0.1% SDS, 65‡C. Major
fragments of 23.0 and 17.0 kb were detected in
EcoRI digested C57BL/6J DNA and major frag-
ments of 25.0 and 4.3 kb were detected in EcoRI
digested M. spretus DNA. The presence or absence
of 25.0- and 4.3-kb EcoRI M. spretus-speci¢c frag-
ments, which cosegregated, was followed in back-
cross mice.
A description of two of the probes and RFLPs for
the loci linked to Galns including Maf and Aprt has
been reported previously [38,39]. One locus has not
been reported previously for this interspeci¢c back-
cross. The probe for actin, K1, skeletal muscle
(Acta1) was a 3.6-kb EcoRI fragment of rat cDNA
that detected major TaqI fragments of 1.6, 1.5, and
1.1 kb in C57BL/6J DNA and major TaqI fragments
of 3.2, 1.5 and 1.1 kb in M. spretus DNA. Recombi-
nation distances were calculated using Map Manag-
er, version 2.6.5. Gene order was determined by min-
imizing the number of recombination events required
to explain the allele distribution patterns.
2.4. Northern blot analysis
Northern blot analysis was performed using mouse
Galns cDNA as a probe to hybridize a BALB/c
mouse MNT blot membrane from Clontech (Palo
Alto, CA, USA). This membrane contained approx-
imately 2 Wg of poly(A) RNA from heart, brain,
spleen, lung, liver, skeletal muscle, kidney and testis.
The Galns cDNA was labeled with [K-32P]dCTP
(Amersham-Pharmacia Biotech) and hybridized ac-
cording to the manufacturer’s instructions.
2.5. Isolation of the genomic clones
The S129vJ mouse genomic DNA library in the V
FIX II vector (Stratagene, La Jolla, CA) was used
for screening. About 2U106 plaques were screened
with Galns mouse cDNA probe labeled with [K-32P]-
dCTP (Amersham-Pharmacia Biotech) using the
multiprime DNA labeling system kit (Amersham).
The plaques were transferred onto nylon membrane
¢lters (Amersham), baked under vacuum at 80‡C for
2 h and hybridized according to standard protocols
with the cDNA probe and with cDNA speci¢c frag-
ment probes. Fourteen positive clones were picked
up. Secondary and tertiary rounds of screening
were done. The positive clones were puri¢ed and
characterized by restriction endonuclease mapping
and Southern blot analysis. The region between
exon 11 and 12 was ampli¢ed by genomic PCR in
a DNA Thermal cycler (Perkin Elmer, Applied Bio-
systems) using primers 11S: 5P-ATTACCGTGG-
CAACACTCTG-3P and 12R: 5-CTGAGTGGGAA-
TCTCTCCCC-3P, each of which is speci¢c for exon
11 and exon 12 sequence, respectively.
2.6. Subcloning and nucleotide sequence analysis
The genomic DNA inserts were excised from the
phage DNA, subcloned into T-vector or pUC 13
vector and then sequenced in both directions using
£uorescent labeled dideoxy nucleotides (Perkin El-
mer Applied Biosystems).
2.7. Primer extension analysis
Poly(A) RNA was isolated from mouse brain,
liver, spleen, testis and kidney using Isogen (Wako,
Japan). The sequence of the primer used for the pro-
cedure is PE 1: 5P-GCTGCTGGGCTGCGGTA-
CAG-3P that is complementary to the sequence
from 9 to 28 bp downstream from the initiation
ATG codon. The primer was end labeled with
[Q-32P]ATP (Amersham) and the transcription initia-
tion site was mapped as described [40]. Electro-
phoretic separation of the product was done on an
8% denaturant gel. M13mp18 was used as a ladder
and was labeled according to the Sequenase Labeled
dCTP Kit’s instructions (Amersham).
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Fig. 1. Nucleotide and deduced amino acid sequence of mouse Galns. The methionine encoded by the ¢rst ATG is numbered as ami-
no acid residue 1. Nucleotide and amino acid numbers are depicted on the right margin. The putative signal sequence cleavage site is
indicated by a vertical arrow. Potential N-glycosylation sites are boxed. The polyadenylation signal in the 3P-untranslated region is
underlined. ‘Ter’ represents termination codon. The full-length Galns cDNA sequence was deposited in GenBank under accession
number AF 111346.
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3. Results and discussion
3.1. Isolation and characterization of mouse Galns
cDNA
Five positive clones were identi¢ed by screening a
Vgt10 mouse library using a 608-bp fragment of hu-
man GALNS cDNA as a probe. However, only one
out of these clones contained the entire coding region
of V2.3 kb (Fig. 1). Sequencing of the ampli¢ed
fragment, showed high homology with human
GALNS cDNA. The full-length Galns cDNA se-
quence of 2343 bp, contained an open-reading frame
of 1560 bp encoding 520 amino acids, being two
residues shorter than that of human cDNA. The de-
duced amino acid sequence had a signal peptide se-
quence consisting of 23 amino acid residues and a
mature protein with 497 amino acid residues. The
mouse leader sequence has the signal peptide cleav-
age site predicted for the human sequence (Fig. 1,
arrow). The mouse cDNA contained two potential
asparagin-linked glycosylation sites located at the
same position as human GALNS. Nucleotide and
amino acid sequence homology between mouse and
human cDNA sequences within the coding region
was 83 and 84%, respectively (see Fig. 2). All mis-
sense mutations identi¢ed so far, except the S135R,
A351V and R376Q, involved amino acids that are
conserved between human GALNS and mouse Galns.
3.2. Expression of the mouse Galns cDNA in de¢cient
¢broblasts
In order to verify whether the full length of mouse
cDNA encoded a functional protein, we performed
transient transfection of pMMYN in de¢cient ¢bro-
blasts. Cells transfected with pMMYN showed sig-
ni¢cant higher activity than those that were trans-
fected with the pCAGGS vector without insert
(Table 1).
3.3. Assignment of the mouse Galns gene to
chromosome 8
The mouse chromosomal location of Galns was
determined by interspeci¢c backcross analysis using
progeny derived from matings of [(C57BL/6JUM.
spretus) F1UC57BL/6J] mice. This interspeci¢c back-
cross mapping panel has been typed for over 2500
loci that are well distributed among all the auto-
somes as well as the X chromosome [36]. C57BL/6J
and M. spretus DNAs were digested with several
enzymes and analyzed by Southern blot hybridiza-
tion for informative restriction fragment length poly-
morphisms (RFLPs), using a mouse cDNA probe.
The 25.0- and 4.3-kb EcoRI M. spretus RFLPs,
were used to follow the segregation of the Galns lo-
cus in backcross mice. The mapping results indicated
Fig. 2. Alignment of amino acid sequence of mouse Galns (top)
and human GALNS (bottom). Dots show the same amino acid
in mouse and human. Dashes show a unique sequence.
Table 1
N-Acetylgalactosamine-6-sulfate sulfatase activity in transfected
cultured skin ¢broblasts of MPS IV A patient de¢cient in
GALNS activity
Plasmid Enzyme activitya (nmol/mg protein/h)
pCAGGS (mock) 0.4 þ 0.3 (n = 3)
pMF(N) 18.5 þ 2.2 (n = 3)
pMMYN 10.8 þ 2.1 (n = 3)
pMF(N), full-length human cDNA in pCAGGS; pMMYN,
full-length mouse cDNA in pCAGGS.
aEnzyme activity was calculated as mean þ S.D.
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that Galns is located in the distal region of mouse
chromosome 8 linked to Maf, Aprt and Acta1.
Although 91 mice were analyzed for every marker
and are shown in the segregation analysis (Fig. 3),
up to 161 mice were typed for some pairs of markers.
Each locus was analyzed in pairwise combinations
for recombinant frequencies using the additional
data. The ratios of the total number of mice exhibit-
ing recombinant chromosomes to the total number
of mice analyzed for each pair of loci and the most
likely gene order are: centromere^Maf (8/161)^Galns
(0/131)^Acta1 (0/105)^Aprt. The recombination fre-
quencies (expressed as genetic distances in centiMor-
gans (cM)+the standard error) are Maf (5.0 þ 1.7)^
[Galns, Acta1, Aprt]. No recombinants were detected
between Galns and Acta1 in 131 animals typed in
common and between Acta1 and Aprt in 105 animals
typed in common, suggesting that the two loci with
each pair are within 2.3 and 2.9 cM of each other
(upper 95% con¢dence limit), respectively.
We have compared our interspeci¢c map of chro-
mosome 8 with a composite mouse linkage map that
reports the map location of many mouse mutations
(provided from Mouse Genome Database, a compu-
terized database maintained at The Jackson Labora-
tory, Bar Harbor, ME). Galns mapped in a region of
Fig. 4. Northern blot analysis of mouse Galns mRNA.
(a) Mouse Galns cDNA probe was hybridized to a Clontech
membrane containing approximately 2 Wg of poly(A) RNA
from various mouse tissues as indicated. (b) L-Actin was used
as hybridization control.
Fig. 3. Galns maps in the distal region of the mouse chromo-
some 8. Galns was placed on mouse chromosome 8 by interspe-
ci¢c backcross analysis. The segregation patterns of Galns and
£anking genes in 91 backcross animals that were typed for all
loci are shown at the top of the ¢gure. For individual pairs of
loci, more than 91 animals were typed. Each column represents
the chromosome identi¢ed in the backcross progeny that was
inherited from the (C57BL/6JUM. spretus) F1 parent. The
shaded boxes represent the presence of a C57BL/6J allele and
white boxes represent the presence of a M. spretus allele. The
number of o¡spring inheriting each type of chromosome is
listed at the bottom of each column. A partial chromosome 8
linkage map showing the location of Galns in relation to linked
genes is shown at the bottom of the ¢gure. Recombination dis-
tances between loci in centiMorgans are shown to the left of
the chromosome and the positions of loci in human chromo-
somes, where known, are shown to the right. References for the
human map positions of loci cited in this study can be obtained
from GDB (Genome Data Base), a computerized database of
human linkage information maintained by The William H.
Welch Medical Library of The Johns Hopkins University (Balti-
more, MD).
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the composite map that lacks mouse mutations with
a phenotype that might be expected for an alteration
in this locus (data not shown).
The distal region of mouse chromosome 8 shares
regions of homology with human chromosomes 16q
and 1q (summarized in Fig. 3) suggesting that the
human homolog of Galns will map to 16q or 1q, as
well. In fact, the human homolog of Galns has been
assigned to 16q24.3 and the mouse and human map-
ping studies are thus in good agreement. The Galns
gene located on mouse chromosome 8 is in a synteny
group with human GALNS located on chromosome
16q.
3.4. Northern blot of mouse Galns mRNA in mouse
tissues
After hybridization of the membrane containing
poly(A) RNA from several tissues with the full-
length cDNA, a single transcript of approximately
2.3 kb was detected in all the tissues analyzed. Fig.
4 shows the levels of the mouse Galns mRNAs in
proportion to that of L-actin in heart, brain, spleen,
lung, liver, skeletal muscle, kidney and testis. The
expression levels were observed in variable amounts,
particularly abundant in kidney and liver and slightly
higher in lung. Expression was lower in heart, brain
and skeletal muscle. Although Northern blot of hu-
man GALNS also showed high expression in kidney
[12], the expression level is not higher than that ob-
served in mouse. By now we could not explain the
reason for the high expression in kidney. The next
step in this research will focus on this subject.
3.5. Structure of the mouse Galns gene
Using the mouse Galns cDNA probe, we screened
a mouse genomic DNA library derived from DNA of
S129vJ mice and isolated ¢ve hybridizing clones. Ini-
tially, these clones were analyzed by restriction en-
zymes and Southern blot analysis using the mouse
Galns cDNA, which revealed that four clones were
overlapping (Fig. 5b; clones 1, 2, 8 and 9) and one
clone was not overlapping with any other clone (Fig.
5b; clone 15). To ¢ll in the separation between clone
8 and clone 15 (intron 11), this region was ampli¢ed
by a PCR technique using the primers 11S and 12R,
based upon the sequence of Galns cDNA. The resul-
Fig. 5. Structure of mouse Galns gene. (a) Restriction map. EcoRI (E), BamHI (B). (b) Region covered by ¢ve overlapped clones and
a PCR product. (c) Exon and intron organization of the mouse Galns gene. Each exon is indicated by its number. Sizes of introns
and exons are shown in Table 2.
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tant fragment, which was 6.2 kb, contained exon 11,
intron 11 and exon 12. Thus the whole entire gene,
including the promoter and the £anking region, was
covered. The mouse Galns gene is formed by 14
exons and 13 introns spanning around 50 kb. The
major restriction sites and the position of the four
overlapping clones, one independent clone and one
connecting PCR fragment are shown in Fig. 5.
In order to make the restriction map, Southern
blot was done using exon speci¢c probes and all
clones were digested with BamHI and EcoRI restric-
tion enzymes. The intron/exon junctions and both
untranslated regions were sequenced from both di-
rections.
Partial nucleotide sequence of the entire gene re-
gion was established: Our sequences contained all
exons, splice junctions, partial sequences of 4.6 kb
that correspond to the 5P-region of the initiation co-
don and partial sequences of 12.8 kb that belongs to
the 3P-region of the termination codon. The intron
sequences were deposited in GenBank under acces-
sion numbers AF112230 to AF112242.
As shown in Table 2, all splice junctions ful¢lled
the GT-AG rule, except exon 8/intron 8 boundary
that shows gc instead of gt. We made a very detailed
search in 100 bp around exon8/intron8 junction and
we could not ¢nd any splice donor consensus se-
quence that would splice out di¡erent intron frag-
ment. Although there are some genes of lysosomal
storage disorders, such as human and canine K-L-
iduronidase genes [41,42] and mouse sulfamidase
gene [43] which exhibit gc instead of gt; the presence
of splicing donor sites that do not obey the GT-AG
rule is very rare: about 0.52% in human [44] and
0.24% in eukaryotes [45].
The introns varied in size from 160 bp in intron 6
to 6.2 kb in intron 1. The intron/exon structure of
the gene and its position is shown schematically in
Fig. 5. Southern blot analysis of mouse genomic
DNA was done using several restriction enzymes
(data not shown) and the results showed the same
restriction enzyme pattern as predicted from the
cloned gene.
3.6. Analysis of the promoter region and localization
of transcription initiation sites
The region between 3461 and +278 (Fig. 6), in-
cluding the immediate 5P-upstream region, exon 1
and the 5P-end of intron 1 of the gene, had a G+C
content of 65% and was rich in CpG dinucleotides
with an observed/expected (Obs/Exp) CpG average
of 0.67 (so called ‘CpG island’) [46]. According to
Gardiner-Garden and Frommer, CpG islands are de-
¢ned as regions that are extended more than 200 bp
with a moving average of Obs/Exp CpG greater than
0.6. CpG islands are stretches of DNA sequences
with high frequency on CpG dinucleotides usually
Table 2
Exon^intron organization of the Galns gene
Exon Size (bp) cDNA position 5P-Splice donor Intron Size (kb) 3P-Splice acceptor
1 s 183 1^183 GACGATgtaagt 1 6.2 ctgcagATGGGG
2 124 184^307 CACCATgtaatt 2 1.1 gtgtagCTAGGG
3 75 308^382 GGAATGgtatgt 3 0.6 ttgcagCTTACA
4 103 383^485 CAAGTGgtgagt 4 2.9 ttccagGCATCT
5 144 486^629 CGGCAGgtaaca 5 1.1 tttcagATTTTA
6 67 630^696 ACACAAgtaagg 6 0.1 ccacagGAAGCG
7 128 697^824 AGGGCGgtgagt 7 0.4 ctgcagGTATGG
8 140 825^964 ACGAAGgcaagt 8 2.4 cctcagGTGGCA
9 104 965^1068 GGCCAGgtgagt 9 3.2 ttgcagGTCAGC
10 137 1069^1205 GGACAGgttggt 10 0.6a caacagGCCCAT
11 103 1206^1308 ACACAGgtacag 11 6.0a ttgcagGGCACT
12 122 1309^1430 ACTCAGgtgagg 12 3.2 ctccagCTTCCA
13 118 1431^1548 GTCATGgtgagc 13 1.8 ttccagAATTGG
14 s 796 1549^2344
Exon sizes were determined from the nucleotide sequence. Approximate intron sizes were determined from the nucleotide sequence de-
rived from genetic mapping and from PCR using exon speci¢c primers.
aFrom PCR.
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associated with housekeeping genes [47] and some
tissue-speci¢c genes [46]. All the housekeeping genes
studied so far have CpG islands. It seems that CpG
islands are essential for the regulation of expression
of vertebrate housekeeping genes. There is a possibil-
ity that any transcription factor could bind upstream
or downstream of the transcription start site accord-
ing to the localization of the CpG island [46].
The transcription start sites of the mouse Galns
gene were determined by primer extension analysis.
Extension of an oligonucleotide primer complemen-
tary to nucleotide +9 to +28 in exon 1 (see Fig. 6),
which was hybridized to poly(A)RNA isolated from
mouse kidney, spleen, brain and liver, was performed
with reverse transcriptase and revealed one major
fragment and several minor fragments. The major
transcription initiation site was located at 90 nt up-
stream from the ATG codon in every tissue analyzed.
Minor initiation transcription sites probably related
with tissue speci¢city, are located downstream to the
major one (from 344 to 375). The control sample
was done using yeast RNA as a template (Fig. 7).
The mouse Galns gene showed a promoter without
TATA box and CCAAT sequence, but contains a
GC rich region with 10 potential Sp1 binding sites
(all of them in reverse orientation: CCGCCC). These
features are characteristics of housekeeping genes.
The promoter region of some genes encoding human
lysosomal enzymes, like the L-subunit of L-hexosami-
nidase, K-glucosidase, acid phosphatase and aryl sul-
fatase A, shows the same pattern: CCAAT and
TATA less promoters, with high GC content and
with potential Sp1 binding sites [48]. Other transcrip-
tion factor binding motifs were searched by com-
puter analysis in this 5P-£anking region and the re-
Fig. 7. Determination of the Galns transcription initiation site
by primer extension analysis. The radiolabeled primer used in
the reaction is shown in the Fig. 6. The products were electro-
phoresed on an 8% denaturant gel. The major transcription ini-
tiation site (indicated by an arrow) is localized at 90 nt up-
stream from the ATG codon. Yeast RNA was used as a
control.
Fig. 6. The sequence is numbered starting from the ATG co-
don. The major transcription initiation site is indicated below
the sequence with a triangle. The putative binding sites for Sp1
transcription factor are boxed. The potential sites for transcrip-
tion factor AP-2 are underlined. An arrow indicates the oligo-
nucleotide used for primer extension analysis. The region that
corresponds to exon 1 is shadowed. 5P-region of intron 1 is
written in lowercase letters.
BBADIS 61919 16-2-00
A.M. Montan‹o et al. / Biochimica et Biophysica Acta 1500 (2000) 323^334 331
sults showed 6 potential binding sites for AP-2
(YCSCCMNSSS).
The organization of the mouse Galns gene and the
human GALNS gene was similar, both having
14 exons and 13 introns with an approximate length
of 50 kb. The coding region showed 84% similarity.
Exons 2^4 and exons 5^8 were clustered, respec-
tively. The promoter lacked TATA and CCAAT
boxes, but had ten putative Sp1 binding sites in
mouse and four in human. The G+C content in
mouse Galns promoter is 67% and in human GALNS
promoter is 70.5% [7]. The mouse Galns gene was
mapped to the distal region of the chromosome 8
sharing regions of homology with the human chro-
mosome 16q [8^10].
The lack of spontaneous models for this disorder
leads to the necessity of creating an engineered one.
The availability of a knock-out animal that function-
ally delete GALNS protein will help us in under-
standing the pathophysiology of the disorder. On
top of that, it will help us to develop innovative
therapy for MPS IV A. Cloning of human GALNS
cDNA has paved the way to develop gene therapy
and recombinant enzyme replacement therapy. Mod-
el animal is indispensable and will help to make a
preclinical trial of novel therapies for MPS IVA.
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